NCT05879250

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Recruiting now Phase 2 Last updated 30 December 2025

What this trial tests

Phase 2 trial testing Biospecimen Collection in Glioblastoma, IDH-Wildtype in 39 participants. Currently enrolling.

Timeline

22 May 2024

Primary endpoint
27 December 2027

27 December 2028

Quick facts

Lead sponsor	Northwestern University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	22 May 2024
Primary completion	27 December 2027
Estimated completion	27 December 2028
Sites	2 locations across United States

Drugs / interventions tested

• Biospecimen Collection — full drug profile →
• Magnetic Resonance Imaging
• Radiation Therapy — full drug profile →
• STAT3 Inhibitor WP1066 — full drug profile →
• Surgical Procedure

Conditions studied

• Glioblastoma, IDH-Wildtype — all drugs for Glioblastoma, IDH-Wildtype →
• MGMT-Unmethylated Glioblastoma — all drugs for MGMT-Unmethylated Glioblastoma →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Glioblastoma, IDH-Wildtype or MGMT-Unmethylated Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting of TAMs: can we be more clever than cancer cells?
   Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
2. STAT3: Key targets of growth-promoting receptor positive breast cancer.
   Jiang RY, Zhu JY, Zhang HP, Yu Y, et al · · 2024 · cited 17× · PMID 39468521 · DOI 10.1186/s12935-024-03541-9
3. Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma.
   Chen Q, Yuan H, Bronze MS, Li M. · · 2025 · cited 16× · PMID 40166931 · DOI 10.1172/jci191422
4. Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.
   Shen Y, Thng DKH, Wong ALA, Toh TB. · · 2024 · cited 12× · PMID 38615034 · DOI 10.1186/s40164-024-00512-8
5. Investigational treatment strategies in glioblastoma: progress made and barriers to success.
   Nelson TA, Dietrich J. · · 2023 · cited 11× · PMID 37796104 · DOI 10.1080/13543784.2023.2267982
6. Starting points for the development of new targeted therapies for glioblastoma multiforme.
   Rusak A, Wiatrak B, Krawczyńska K, Górnicki T, et al · · 2025 · cited 9× · PMID 39531784 · DOI 10.1016/j.tranon.2024.102187
7. Combining organotypic tissue culture with light-sheet microscopy (OTCxLSFM) to study glioma invasion.
   Haydo A, Wehle A, Herold-Mende C, Kögel D, et al · · 2023 · cited 8× · PMID 37938214 · DOI 10.15252/embr.202356964
8. Glioma Stem Cells-Features for New Therapy Design.
   Pećina-Šlaus N, Hrašćan R. · · 2024 · cited 7× · PMID 38672638 · DOI 10.3390/cancers16081557